Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 4/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21081675 | 1.00 | HTR2A (0.47) | HTR2AHRH1TSHRNPSR1MMP2 | |
| SCHEMBL21736741 | 0.89 | HTR2A (0.45) | HTR2AHRH1TSHRNPSR1MMP2 | |
| SCHEMBL24677819 | 0.88 | HTR2A (0.44) | HTR2AHRH1TSHRNPSR1MMP2 | |
| SCHEMBL21787357 | 0.88 | HTR2A (0.44) | HTR2AHRH1TSHRNPSR1MMP2 | |
| SCHEMBL21742959 | 0.87 | TSHR (0.39) | TSHRNPSR1MMP2MMP3ALDH1A1 | |
| SCHEMBL23052583 | 0.86 | MMP1 (0.47) | TSHRNPSR1MMP2MMP3ALDH1A1 | |
| SCHEMBL21081686 | 0.86 | MMP1 (0.47) | TSHRNPSR1MMP2MMP3ALDH1A1 | |
| SCHEMBL13032995 | 0.85 | HTR2A (0.44) | HTR2AHRH1MMP2MMP3NAAA | |
| SCHEMBL23052581 | 0.85 | KDM4E (0.42) | TSHRNPSR1ALDH1A1KMT2APOLB | |
| SCHEMBL24677821 | 0.85 | HTR2A (0.41) | HTR2AHRH1TSHRNPSR1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717574-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
| US-10888624-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2021-01-12 | — | — | US | disclosed |
| US-20200069810-A1 | THERAPEUTIC DENDRIMERS | ASTRAZENECA PHARMACEUTICALS LP | 2020-03-05 | — | — | US | disclosed |
| US-10314920-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314920-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | HTR2A 4238/4885HRH1 4089/4885TSHR 2456/4885 |
| US-11717574-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | HTR2A 4238/4885HRH1 4089/4885TSHR 2456/4885 |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | HTR2A 4024/4885HRH1 3040/4885TSHR 1466/4885 |
| US-10888624-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | HTR2A 4238/4885HRH1 4089/4885TSHR 2456/4885 |
| US-20200069810-A1 | THERAPEUTIC DENDRIMERS | CD44, ITGAV, FOLR1 | HTR2A 4238/4885HRH1 4089/4885TSHR 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.